Haemonetics (HAE) Cash from Financing Activities (2009 - 2026)

Haemonetics has reported Cash from Financing Activities for 18 years, with the latest figure at -$101.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 32.98% year-over-year to -$101.5 million; the trailing twelve-month figure through Mar 2026 stood at -$178.5 million (down 264.0% YoY), and the FY2026 full-year result was -$178.5 million, down 264.0% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$101.5 million, down from $2.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $333.7 million in Q2 2024, with the low at -$151.4 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$7.9 million, with a median of -$8.0 million recorded in 2022.
• Peak annual rise in Cash from Financing Activities reached 55901.34% in 2024, while the deepest fall reached 3861.45% in 2024.
• Tracing HAE's Cash from Financing Activities over 5 years: stood at -$49.7 million in 2022, then soared by 320.27% to $109.4 million in 2023, then tumbled by 98.74% to $1.4 million in 2024, then surged by 47.32% to $2.0 million in 2025, then slumped by 5092.57% to -$101.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$101.5 million (Q1 2026), $2.0 million (Q4 2025), and -$76.6 million (Q3 2025), per Business Quant data.

Peer Comparison